Notice of Trading Update

RNS Number : 2712O

Oncimmune Holdings PLC

29 May 2020

 

29 May 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 Notice of Trading Update

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, will be announcing a trading update for the full year ended 31 May 2020 on Thursday, 4 June 2020.

Dr Adam M Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, and Professor Tariq Sethi, Chief Scientific Officer, will host an online presentation and conference call for analysts and investors at 10:30am BST on 4 June 2020.

The Company will also be conducting live virtual laboratory tours with lead scientists at its sites in Nottingham, UK and Dortmund, Germany. This will provide the attendees with a rare insight into the science behind Oncimmune's EarlyCDT tests and its core immune profiling technology service, ImmunoINSIGHTS.

For video conference details please contact Alex Davis at FTI Consulting at [e-mail] or 020 3727 1000.

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

[phone]

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT® Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT?

EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells. EarlyCDT Lung is the world's most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor's surgery.

Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).

What is ImmunoINSIGHTS?

The ImmunoINSIGHTS service leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling enhanced development of targeted and more effective treatments. 

For more information, visit  www.oncimmune.com

 

END

 

 

NORFLFFEETITFII